Background: The Positive and Negative Syndrome Scale (PANSS) is widely used for patients with schizophrenia. This scale is reliable and valid. The PANSS was translated and validated in several languages. Objective: The aim of this study was to translate and validate the PANSS in the Arab population. Subjects and Methods: The PANSS was translated into formal Arabic language using the back-translation method. 101 Arab patients with schizophrenia and 98 Arabs with no diagnosis of any mental disorder were recruited. The Arabic version of the Mini International Neuropsychiatric Interview (MINI-6) was used as a diagnostic tool to confirm the diagnosis of schizophrenia or rule out any diagnosis for the healthy control group. Reliability of the scale was assessed by calculating internal consistency, interrater reliability and test-retest reliability. Construct validity was assessed using the Arabic version of the MINI-6. PANSS total scores were correlated with the Clinical Global Impression-Severity scale. Results: Our findings showed that the internal consistency was good (0.92). Scores on the PANSS of the patients were much higher than those of the healthy controls. The PANSS showed good interrater reliability and test-retest reliability (0.92 and 0.75, respectively). In comparison with the MINI-6, the PANSS showed good sensitivity and specificity, which implies good construct validity of this version. Conclusion: In conclusion, the Arabic version of the PANSS is a reliable and valid instrument for the assessment of patients with schizophrenia in the Arab population.

Keywords:
Validation, Cultural adaptation, Schizophrenia, Arabic Positive and Negative Syndrome Scale
1.
McGrath J, Saha S, Ghant D, Welham J: Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, text revision. Washington, American Psychiatric Association, 2000.
3.
Kay SR: Positive and Negative Syndromes in Schizophrenia: Assessment and Research. Clinical and Experimental Research. New York, Monograph Series of the Department of Psychiatry Albert Einstein College of Medicine of Yeshiva University, 1991.
4.
Reddy VP, Kozielska M, Suleiman AA, Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GMM, Danhof M, Proost JH: Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia part I: the use of PANSS total score and clinical utility. Schizophr Res 2013;146:144-152.
5.
Levine SZ, Goldberg Y, Samara M, Davis JM, Leucht S: Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. Schizophr Res 2015;164:122-126.
6.
Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S: Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015;72:14-21.
7.
Tandon R, Belmaker RH, Gattaz WF, Lopex-Ibor JJ, Okasha A, Singh B, Stein DJ, Olie J, Fleischhacker WW, Moeller H: World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38.
8.
Opler LA, Ramirez PM: Use of the Positive and Negative Syndrome Scale (PANSS) in clinical practice. J Pract Psychol Behav Health 1998;4:157-162.
9.
Lancon C, Reine G, Llorca PM, Auquier P: Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS). Acta Psychiatr Scand 1999;100:237-243.
10.
Von Knorring L, Lindstrom E: The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia: construct validity and interrater reliability. Acta Psychiatr Scand 1992;86:463-468.
11.
Phillips MR, Xiong W, Wang RW, Gao YH, Wang XQ, Zhang NP: Reliability and validity of the Chinese versions of the scales for assessment of positive and negative symptoms. Acta Psychiatr Scand 1991;84:364-370.
12.
Peralta V, Cuesta MJ: Validation of Positive and Negative Symptom Scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1994;22:171-177.
13.
Kostakoğlu AE, Batur S, Tiryaki A: Reliability and validity of the Turkish version of the Positive and Negative Syndrome Scale (PANSS). Türk Psikol Derg 1999;14:23-32.
14.
Ivanova E, Renzik A, Opler M, Khan A, Gao L: Validation and normalization of the Russian version of the Positive and Negative Syndrome Scale (PANSS-RU) in schizophrenia: a preliminary findings. Eur Psychiatry 2014;29:1.
15.
Yamada H, Kikumoto K, Masui K, Mashiko S: Reliability of the Japanese version of the positive and negative syndrome scale (PANSS). Jpn J Clin Psychiatry 1993;22:609-614.
16.
Saab R, Moussaoui D, Tabet CC, El Hamaoui Y, Salamoun MM, Mneimneh ZN, Karam EG: Epidemiology of schizophrenia and related disorders in the Arab world. Arab J Psychiatry 2011;22:1-9.
17.
Abou-Saleh MT, Ghubash R, Daradkeh TK: Al Ain community psychiatric survey I: prevalence and socio-demographic correlates. Soc Psychiatry Psychiatr Epidemol 2001;36:20-28.
18.
Ghuloum S, Bener A, Abou-Saleh MT: Prevalence of mental disorders in adult population attending primary health care setting in Qatari population. J Pak Med Assoc 2011;61:216-221.
19.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22-33.
20.
Kadri N, Agoub M, El Gnaoui S, Alami KM, Hergueta T, Moussaoui D: Moroccan colloquial Arabic version of the Mini International Neuropsychiatric Interview (MINI): qualitative and quantitative validation. Eur Psychiatry 2005;20:193-195.
21.
Ghanem M, Gadallah M, Meky FA, Mourad S, El-Kholy G: National survey of prevalence of mental disorders in Egypt: preliminary survey. East Mediterr Health J 2009;15:65-75.
22.
Qatar Statistic Authority: Census 2010. 2010. http://www.qsa.gov.qa/QatarCensus/General_Results.aspx.
23.
Guy W: Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, National Institute of Mental Health, 1976.
24.
Addington D, Addington J, Schissel B: A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-251.
25.
Prince M: Measurement validity in cross-cultural comparative research. Epidemiol Psichiatr Soc 2008;17:211-220.
26.
Guilford JP: Psychometric Methods, ed 2. New York, McGraw-Hill, 1954.
27.
MacCallum RC, Widaman KF, Zhang S, Hong S: Sample size in factor analysis. Psychol Methods 1999;4:84-99.
28.
Bressan RA, Chaves AC, Pilowsky LS, Shirakawa I, Mari JJ: Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. Psychiatry Res 2003;117:47-56.
29.
Nunnally J: Psychometric Theory. New York, McGraw Hill, 1978.
30.
Cicchetti DV: Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 1994;6:284-290.
31.
Cohen J: Statistical Power Analysis for the Behavioral Sciences, revised. Hillsdale, Erlbaum, 1988.
32.
Kay S, Fiszbein A, Opler L: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
33.
Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, Yoon DJ, Jho KH, Koo YJ, Lee JY, Cho IH, Park YH, Kim KS, Kim YS: Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale. J Korean Neuropsychiatr Assoc 2001;40:1090-1105.
34.
Igarashi Y, Hayashi N, Yamashina M, Otsuka N, Kuroki N, Anzai N, Kazamatsuri H: Interrater reliability of the Japanese version of the Positive and Negative Syndrome Scale and the appraisal of its training effect. Psychiatry Clin Neurosci 1998;52:467-470.
35.
Posser ES, Csernansky JG, Kaplan J, Thiemann S, Becker TJ, Hollister LE: Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 1987;175:100-105.
36.
Carpenter W, Heinrichs D, Alphs L: Treatment of negative symptoms. Schizophr Bull 1985;11:440-452.
37.
Sarro S, Duenas RM, Ramirez N, Arranz B, Martinez R, Sanchez JM, Gonzalez JM, Salo L, Miralles L, San L: Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. Schizophr Res 2004;68:349-356.
38.
Kim SW, Kim SJ, Yoon BH, Kim JM, Shin IS, Hwang MY, Yoon JS: Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Res 2006;144:57-63.
39.
Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S: Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 2008;98:318-322.
40.
Rabinowitz J, Ingham M: To What Extent Do the PANSS and CGI-S Overlap? Florida, National Institute of Mental Health, 2005.
41.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR: What does the PANSS mean? Schizophr Res 2005;79:231-238.
42.
Lako IM, Bruggeman R, Knegtering H, Wiersma D, Schoevers RA, Slooff CJ, Taxis K: A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J Affect Disord 2012;140:38-47.
43.
Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H: Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol 2010;30:446-449.
44.
Levine SZ, Rabinowitz J, Rizopoulos D: Recommendations to improve the positive and negative syndrome scale (PANSS) based on item response theory. Psychiatry Res 2011;188:446-452.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.